4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1- (3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor1 receptor antagonist. II. Characterization in rodent models of stress-related disorders

Journal of Pharmacology and Experimental Therapeutics

Volumn 301, Issue 1, 2002, Pages 333-345

  Griebel, Guy ^a   Simiand, Jacques ^a   Steinberg, Régis ^a   Jung, Mireille ^a   Gully, Danielle ^a   Roger, Pierre ^a   Geslin, Michel ^a   Scatton, Bernard ^a   Maffrand, Jean Pierre ^a   Soubrié, Philippe ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 1,3 THIAZOL 2 AMINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; ANTALARMIN; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DIAZEPAM; FLUOXETINE; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DEPRESSION; DISTRESS SYNDROME; DRUG ACTIVITY; EXPLORATORY BEHAVIOR; FEAR; FORCED SWIMMING TEST; HYPERTHERMIA; LIGHT DARK CYCLE; MALE; MAZE TEST; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SOCIAL BEHAVIOR; STRESS; VOCALIZATION; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; CONFLICT (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FEAR; HYPOTHERMIA; MALE; MEMORY; MICE; MOTOR ACTIVITY; NOREPINEPHRINE; PUNISHMENT; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SOCIAL ISOLATION; STRESS, PSYCHOLOGICAL; SWIMMING; THIAZOLES; VOCALIZATION, ANIMAL;

EID: 18344394149     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.301.1.333     Document Type: Article

References (40)

1. The effects of corticotrophin releasing factor (CRF) and handling stress on behavior in the elevated plus-maze test of anxiety
2. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: Behavioral, endocrine and neurochemical effects in the rat
3. A new method for the rapid screening of minor tranquillisers in mice
4. 1 antagonist, CP-154,526, in the Vogel and ultrasonic vocalization (USV) tests in rats
5. Corticotrophin-releasing factor receptors: From molecular biology to drug design
6. Understanding corticotropin releasing factor neurobiology: Contributions from mutant mice
7. 1 receptor antagonist in the separation-induced vocalization model of anxiety in rat pups
8. Role of catecholamines in the frontal cortex in the modulation of basal and stress-induced autonomic output in rats
9. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?
10. Characterization of the behavioral profile of the non peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents: Comparison with diazepam and buspirone
11. Genetic differences in the mouse defense test battery
12. 1 receptor antagonist. I. Biochemical and pharmacological characterization
13. Corticotropin-releasing factor antagonists as novel psychotherapeutics
14. 1 receptor antagonist
15. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action
16. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
17. Corticotropin-releasing hormone in depression and post-traumatic stress disorder
18. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice
19. The use of a plus-maze to measure anxiety in the mouse
20. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity
21. Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: An in vivo microdialysis approach in guinea pig
22. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats
23. A new test for aggression in rats without aversive stimulation: Differential effects of d-amphetamine and cocaine
24. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents
25. Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs
26. Are CRF receptor antagonists potential antidepressants?
27. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001
28. Pharmacological validation of the chronic mild stress model of depression
29. Validation of open closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
30. Depression: A new animal model sensitive to antidepressant treatments
31. 1A receptor agonist
32. Behavioral effects of central administration of the novel CRF antagonist astressin in rats
33. Effects of the NK2 receptor antagonist, SR48968 on the CRF-induced activation of the NE locus coeruleus-prefrontal cortex system of the rat
34. Neuropeptides and stress: Preclinical findings and implications for pathophysiology
35. Animal models for the study of anti-anxiety agents: A review
36. Characterization of a 41 residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin
37. A simple and reliable conflict procedure for testing anti-anxiety agents
38. An animal model of anhedonia
39. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated